Showing 81 - 100 results of 136 for search '"Yale Cancer Center"', query time: 0.10s Refine Results
  1. 81
  2. 82
  3. 83
  4. 84
  5. 85
  6. 86
  7. 87
  8. 88
  9. 89
  10. 90
  11. 91
  12. 92
  13. 93
  14. 94
  15. 95

    Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature by Jan Paredes Mogica, Haiming Tang, Yuanxin Liang, Minghao Zhong, Pei Hui, Malini Harigopal, Uma Krishnamurti, Neal A. Fischbach, Haiying Zhan

    Published 2023-12-01
    “…Methods: We identified 104 patients with localized HER2 IHC 3+ breast cancer who received neoadjuvant trastuzumab(T)/pertuzumab(P) containing chemotherapy at Yale Cancer Center between 2012 and 2022. Patients were divided into 3 cohorts by response and HER2 IHC in the residual disease: Cohort 1 pathologic complete response (pCR), Cohort 2 pre-treatment IHC 3+/post treatment IHC 1+/2+, and Cohort 3 pre-treatment IHC 3+/post-treatment IHC 3+. …”
    Get full text
    Article
  16. 96
  17. 97
  18. 98
  19. 99
  20. 100